SuperworthFemasys EPS FEMY
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$4.53
- Latest quarter, Q2 FY26
- −$1.33
- Fiscal year 2025
- −$10.98
Femasys' earnings per share was −$4.53 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.33.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$10.98 | n/a |
| FY2024 | −$16.80 | n/a |
| FY2023 | −$18.80 | n/a |
| FY2022 | −$19.00 | n/a |
| FY2021 | −$55.00 | n/a |
| FY2020 | −$144.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.33 | n/a | −$4.53 | |
| Q1 FY26 | $0.00 | n/a | −$6.38 | |
| Q4 FY25 | −$1.20 | n/a | −$10.98 | |
| Q3 FY25 | −$2.00 | n/a | −$14.18 | |
| Q2 FY25 | −$3.18 | n/a | −$16.98 | |
| Q1 FY25 | −$4.60 | n/a | −$18.00 | |
| Q4 FY24 | −$4.40 | n/a | −$16.80 | |
| Q3 FY24 | −$4.80 | n/a | −$16.60 | |
| Q2 FY24 | −$4.20 | n/a | −$17.00 | |
| Q1 FY24 | −$3.40 | n/a | −$17.20 | |
| Q4 FY23 | −$4.20 | n/a | −$18.80 | |
| Q3 FY23 | −$5.20 | n/a | −$19.40 |
Against its peers
Companies in Medical - Instruments & Supplies nearest Femasys' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| FEMYFemasys | −$4.53 | |
| NEPHNephros | $0.16 | +33% a year |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| Peer median | $0.41 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Femasys
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.